Abstract: A restraining device for an animal. A body having a base and two spaced-apart walls define a cavity to receive the animal. At least one pair of side restraining members is mounted to one of the walls of the body. Each restraining member is displaceable away from the wall and into the cavity to engage a side of the animal. An overhead restraining member is mounted to the body above the base. The overhead restraining member is displaceable toward and away from the base to engage the animal. A tightening mechanism is mounted to the body and has at least one rotatable rod. The first end of the rod has a rotatable handle to rotate the rod and the second end has a cam engaging one of the side restraining members. The handle rotates the cam and displaces the side restraining members into the cavity.

Abstract: A restraining device for an animal. A body having a base and two spaced-apart walls define a cavity to receive the animal. At least one pair of side restraining members is mounted to one of the walls of the body. Each restraining member is displaceable away from the wall and into the cavity to engage a side of the animal. An overhead restraining member is mounted to the body above the base. The overhead restraining member is displaceable toward and away from the base to engage the animal. A tightening mechanism is mounted to the body and has at least one rotatable rod. The first end of the rod has a rotatable handle to rotate the rod and the second end has a cam engaging one of the side restraining members. The handle rotates the cam and displaces the side restraining members into the cavity.

Abstract: The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.

Abstract: The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.

Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.